Aptevo Therapeutics Return on Equity

Aptevo Therapeutics (APVO) currently reports a ROE of -487.63%. That is below the Healthcare sector average of 20.77%. Use the charts on this page to explore Aptevo Therapeutics's ROE history and peer comparisons.

Aptevo Therapeutics's ROE of -487.63% is lower than the Healthcare sector average of 20.77%. That is roughly 2448.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Aptevo Therapeutics's current -487.63% should be judged against Healthcare norms (sector average: 20.77%) and against APVO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -487.63%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Aptevo Therapeutics, and consider following APVO for alerts when major investors trade the stock.

Aptevo Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -487.63% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing APVO with unrelated industries.